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ABSTRACT
We present an interaction of meropenem with valproate in an 
epileptic child, leading to seizure exacerbations owing to the 
rapid lowering of serum valproate concentration. An increase of 
seizure frequency and somnolence were observed in the patient 
after the addition of meropenem to the treatment, and a rapid 
decline of valproate serum concentrations was observed after two 
doses of meropenem. This decline was the most likely cause of 
the increase in seizure frequency. The dosage of valproate was 
raised and meropenem was stopped. Two days later, the seizures 
stopped. Five days later, the serum valproate concentrations raised 
to three fold, and they rose to therapeutic levels four weeks later. 
To avoid drug interaction that reduces the serum concentration 
of valproate, meropenem in epileptic patients using valproate 
for the treatment of epilepsy should be administered cautiously.
If concominant administration is essential, close observation of 
serum concentration of valproate and clinical course of the patient 
are necessary.
Keywords: Carbapenems, Drug interactions, Meropenem, 
Seizures, Valproate
ÖZET
Bu yazıda, meropenem ve valproat etkileşimine sekonder olarak 
serum valproat düzeyinin hızlı düşmesi sonucu nöbetleri alevlenen 
epileptik bir çocuk sunulmuştur. Hastanın tedavisine meropenem 
eklendikten ve iki doz kullanıldıktan sonra nöbet sıklığı ve 
somnolans durumunda artış ortaya çıkan hastanın serum valproat 
düzeyinde ani düşme görüldü. Nöbet sıklığındaki artışın valproat 
serum düzeyinin düşüşüne bağlı olduğu düşünüldü. Hastanın 
valproat dozu artırılarak meropenem tedavisi kesildikten iki gün 
sonra nöbetler sona erdi. Beş gün sonra serum valproat düzeyi üç 
katına, dört hafta sonra ise terapötik düzeylere yükseldi. Serum 
valproat düzeyinin düşmesine neden olan ilaç etkileşimine neden 
olmamak için, valproat kullanan epileptik hastalarda meropenem 
dikkatle uygulanmalı, iki ilacın birlikte kullanımı mutlaka 
gerekliyse hastanın klinik durumu ve serum valproat düzeyi 
yakından izlenmelidir.
Anahtar kelimeler: İlaç etkileşimi, Karbapenemler, Meropenem, 
Nöbetler, Valproat
Introduction
Meropenem, is a carbapenem antibiotic, and has a broad 
spectrum of antimicrobial activity. Valproate is widely 
used in the treatment of epileptic seizures in children. In 
recent years, low serum concentrations of valproate were 
reported in children and adults receiving concomitant 
treatment with meropenem [1]. We present an interaction of 
meropenem with valproate in an epileptic child, leading to 
seizure exacerbations owing to the rapid lowering of serum 
valproate concentration. 
Case report
This report describes a fourteen-year-old epileptic inpatient 
girl who had received concurrent treatment with meropenem 
for the treatment of lobar pneumonia and pleuresia, and 
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valproate for the treatment of epilepsy. The patient has been 
epileptic since three-months of age, with motor and mental 
retardation, and has been diagnosed as Lennox-Gastaut 
syndrome. The patient was receiving valproate + lamotrigine 
+ clobazam + levetiracetam treatment by oral route during 
the last three years because of resistant seizures. Serum 
levels of valproate were observed within the therapeutic 
range (50 – 100 µg/ml) during the follow-up period.
The patient was admitted to the emergency department 
with the complaints of cough, fever, malaise, and feeding 
difficulty during the last four days. She was examined as 
dyspneic, tachypneic, cyanotic, and dehydrated. Ceftriaxone 
and vancomycine were started as an initial therapy for lobar 
pneumonia. On the 2nd day of hospitalization, her fever and 
respiratory distress were relieved. On the 3rd day, serum 
level of valproate was 68.31 µg/mL, within the therapeutic 
range (Table I). On the 4th day, the patient was clinically 
worse and pleuresia was diagnosed on the chest X-ray and 
ultrasonography. Meropenem was started on the 5th day with 
1 gr of dose twice daily intravenously, and ceftriaxone was 
discontinued. On the 6th day the patient became lethargic, 
and numerous generalised myoclonic seizure episodes 
occurred involving her face, arms, and legs. After two doses 
of meropenem, serum level of valproate, was 12.18 µg/mL. 
The increase in seizure frequency and somnolence were 
considered to be due to the rapid decline of valproate serum 
concentration after addition of meropenem to the treatment. 
This situation was the most likely cause of increase in 
seizure frequency. The dosage and frequency of valproate 
were raised from 1000 mg/day (500 mg, every twelve hours) 
to 1050 mg/day (350 mg, every six hours), with nearly the 
same dose, and meropenem was stopped on day seven. 
After meropenem therapy was discontinued, piperacillin/
tazobactam was started in addition to vancomycin. Two 
days later, the seizures were taken under control. Five days 
later, the serum valproate concentration rose to three-fold 
and four weeks later, on day 36, concentrations rose up to 
therapeutic levels (Table I). The drug interaction probability 
scale indicates a highly probable drug interaction between 
valproate and meropenem use in our patient. For this reason, 
the seizures were considered to be related to the concurrent 
administration of meropenem and valproate.
Antibiotherapy was completed on day 18, the patient 
recovered from pneumonia and pleurisy, and was discharged 
from the hospital.
Discussion
Meropenem is a carbapenem antibiotic with a broad spectrum 
of activity against gram-positive and gram-negative aerobic 
and anaerobic organisms [2]. It has been used in critically 
ill patients with severe infections, such as pneumonia and 
sepsis. The risk of seizure occurrence increases in patients 
using carbapenems [3]. Meropenem has a lower risk (0.02 - 
0.1%) [4] of seizure than imipenem (0.4 - 0.9%), probably 
due to structural differences, and their lower affinity for 
gamma-aminobutyric acid receptors in the central nervous 
system [2]. For this reason, meropenem is considered one of 
the best choices for patients with severe infections who have 
epilepsy or other neurologic diseases. 
Valproate is a widely used anti-epileptic drug in the 
treatment of epilepsy including generalized tonic-clonic 
Table 1. Valproate serum levels, valproate dose and frequency, and seizures during meropenem therapy. Valproate serum levels before, 
during, and after meropenem therapy. After the patient was discharged on day 18, the serum level of valproate increased up to 58.11 µg/
mL on day 36.
Day 3 Day 5 Day 6 Day 7 Day 9 Day 17 Day 36
Valproate serum levels 
(µg/mL) 68.31 12.18 36.7 39.06 58.11
Treatment with
meropenem
No Two doses, 
every 12 
hours
Discontinued No No No No
Seizures No No Yes Yes No No No 
Dose (mg) and frequency 
of valproate
500, every 
8 hours
500, every 
8 hours
350, every 8 hours 350, every 8 
hours
350, every 
8 hours
350, every 
8 hours
350, every 
8 hours
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and partial seizures [2]. This drug is heavily attached to 
plasma proteins and largely metabolized in the liver by 
glucuronidation (70%). Beta-oxidation, omega-oxidation 
and hydroxylation are minor pathways in the metabolization 
of valproate. All carbapenems, including meropenem, have 
lowered the serum concentration of valproate in epileptic 
patients to a sub-therapeutic level. Because serum valproate 
concentration was not decreased by carbapenems in 
hepatectomized rats, the liver is considered as the key organ 
for the decrease of valproate concentration by carbapenems. 
Valproate-glucuronidase in human liver microsomes, 
and especially in cytosol, was inhibited by carbapenems 
[5]. The interaction between valproate and a carbapenem 
(panipenem/betamipron) was first reported by Nagai et al 
[6] in two children in 1997. Other cases have been reported 
since then; as in our case, seizures have occurred during 
concomitant therapy of valproate and meropenem [1,2,7,8]. 
Decline in valproate serum concentration and seizures 
were observed within 24 hours after concomitant 
administration of valproate and meropenem in our patient. 
The most rapid decrease of serum valproate within 24 [7] 
and 36 hours [6] were reported in other studies. In some 
other reports, this decline was observed within three to 
seven days after the initiation of meropenem to patients 
receiving valproate therapy [1]. This rapid decline in serum 
concentration of valproate is not explained with enzyme 
induction because this mechanism usually requires several 
days [9]. Inhibition of plasma protein binding of valproate 
by carbapenems has been suggested for the interaction 
between valproate and carbapenems [5,7]. Valproate has a 
high protein-binding ratio (90 - 95%), whereas,  meropenem 
is a low (2%) protein bound drug. For this reason, these 
rapid declines may not be explained by the mechanism of 
competition in protein binding [10]. The most comprehensive 
research study on this topic was undertaken by Yokogawa et 
al [10]. They studied the effects of meropenem on valproate 
metabolism in rabbits, because metabolism of this drug is 
similar to that in humans. This study indicated that urinary 
excretion of valproate-glucuronide, and suppression of 
valproate-glucuronide hydrolysis in the liver were increased 
at the time of concomitant administration of valproate and 
meropenem [10]. Furthermore, suppression of valproate-
glucuronide hydrolysis in the gastrointestinal tract was 
also increased in this concomitance [10]. The mechanisms 
of rapid decline of valproate serum concentration has been 
elucidated by recent studies. Some studies have indicated 
that the clearance of valproate is increased by meropenem 
by increasing the urinary excretion of valproate glucuronide 
[7,8,10]. Other mechanisms in which decreases occur in the 
serum levels of valproate by carbapenems are: inhibition 
of the hydrolysis of valproate glucuronide, increase in the 
glucuronidation of valproate, suppression of enterohepatic 
recirculation of valproate, and increase in the erytrocyte 
distribution of valproate, which induce the decrease in 
serum levels of valproate [11]. The reduced blood levels of 
valproate at a fairly short time period in our patient may be 
caused by decreased hydrolysis of valproate-glucuronide 
conjugation resulting from eliminating of microorganism 
with beta-glucuronidase activity owing to antibacterial 
drugs. For these reasons, reabsorption of free valproate 
decreases.
Carbapenems may induce seizures during acute 
neurologic diseases as intracranial infections, hemorrhage, 
stroke, trauma, and tumors [3,9]. None of these have occurred 
in our patient during concomitant therapy of valproate and 
meropenem. 
In the reported cases to date, none of the antibiotics (i.e. 
ceftazidime, cefotaxime, amikacin, vancomycin, ampicillin, 
tobramycin, and clindamycin) other than carbapenems have 
caused a decline of the serum concentration of valproate. 
In addition, serum valproate concentrations increased after 
the termination of carbapenems according to these reports 
[1]. Rapidly changed serum concentrations of valproate is 
not consistent with the induction of enzymes participated in 
valproate metabolism process.  
Serum valproate concentration was decreased while 
under meropenem treatment  and gradually returned to 
normal levels after cessation of meropenem in a reported 
14-year old girl with cystic fibrosis and multidrug resistant 
pulmonary infection with intravenous antibiotics [12]. Her 
serum valproate concentration kept low despite elevated 
daily dosing of valproate and a loading dose. Finally,  on 
the 18th day of cessation of meropenem the blood valproate 
level reached its normal value. The daily doses were 
increased, however, the loading dose was not used in our 
case. The low blood levels of valproate until the 36th day 
may be related with inadequate dose of valproate without the 
loading dose. Conversely, seizures were controlled after two 
days and the serum valproate concentration rose to three-
fold after the discontinuation of meropenem and increased 
daily valproate doses. Therefore, the loading valproate dose 
with increased daily doses may be used to increase the blood 
valproate levels.
Clinicians should be aware of the interaction between 
valproate and carbapenems and of the possible clinical 
consequences like increasing the frequency of epileptic 
seizures and/or status epilepticus. To avoid drug interaction 
that reduces the serum concentration of valproate, care 
should be taken when administering meropenem in epileptic 
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patients using valproate for the treatment of epilepsy. If 
possible,  another antibiotic, except carbapenems, should be 
used in patients using valproate or the antiepileptic therapy 
should be switched to another drug other than valproate. 
However, this second option may not be feasible in many 
patients if their seizures are controlled only with valproate. 
In addition, if the antiepileptic drug regime has changed, 
at least two – four weeks will be required for sufficient 
levels of the new antiepileptic drug to be attained [1]. If 
concomitant administration is essential, close observation 
of serum concentration of valproate and clinical course of 
patient are necessary. 
There were not plasma levels of other antiepileptic drugs 
excluding valproate.   
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